Introduction
Few patent cases have shaped India’s innovation landscape as profoundly as Novartis AG v. Union of India. Decided by the Supreme Court on April 1, 2013, the case revolved around a cancer drug called Glivec (imatinib mesylate), and a simple but powerful legal question: when does a small change in a known drug deserve a new patent?
The Court’s answer changed how pharmaceutical patents are examined in India and how global innovators approach Indian filings. At the heart of it lies Section 3(d) of the Patents Act, 1970 - a clause designed to stop “evergreening,” or repeated patenting of minor modifications of existing drugs.
If you’re developing or commercializing pharmaceuticals, or planning to file patents in India, understanding this case isn’t optional-it’s essential.
Section 3(d) in Simple Terms
Section 3(d) says that the mere discovery of a new form of a known substance is not patentable, unless it shows enhanced efficacy.
In plain language: if you already know a molecule that works as a drug, you can’t claim a new patent for a salt, polymorph, or crystalline version unless you can prove that it performs significantly better as a medicine.
The Explanation to Section 3(d) lists examples-salts, esters, ethers, polymorphs, metabolites, pure forms, particle sizes, and others-to emphasize what counts as a “new form.” These are not per se excluded, but they must demonstrate enhanced therapeutic efficacy, not just better properties like stability or flowability.
The law aims to balance two competing goals:
Reward true innovation, and
Protect public access to medicines by preventing artificial extensions of patent life.
The Story Behind Novartis and Glivec
In the late 1990s, Novartis developed Imatinib Mesylate, a breakthrough molecule for treating chronic myeloid leukemia (CML). The original compound was already known in earlier patents filed abroad. Later, Novartis discovered a beta-crystalline form of imatinib mesylate, claiming it offered better bioavailability and stability, and applied for a patent in India in 1998.
By the time India’s patent law started recognizing pharmaceutical product patents in 2005, Novartis’s application was still pending. The Indian Patent Office (IPO) examined it under the newly amended Patents Act and rejected it, citing Section 3(d). The IPO reasoned that the new crystalline form was merely a different version of an existing compound, with no proven improvement in therapeutic efficacy.
Novartis appealed to the Madras High Court, and eventually the matter reached the Supreme Court of India.
What the Supreme Court Decided
The Supreme Court’s 112-page judgment - delivered by Justices Aftab Alam and Ranjana Desai - is a landmark in Indian patent jurisprudence.
Here are its key holdings:
Enhanced efficacy means therapeutic efficacy.
The Court ruled that “efficacy” in Section 3(d) refers to the drug’s therapeutic efficacy, not physical properties like stability, solubility, or hygroscopicity. These qualities may be advantageous but don’t directly make the drug better at curing disease.Bioavailability isn’t enough.
Novartis showed that the beta-crystalline form had improved bioavailability. The Court accepted that fact but said better absorption alone doesn’t necessarily mean improved therapeutic outcome.Burden of proof is on the applicant.
It’s up to the applicant to demonstrate with data how the new form improves the drug’s therapeutic effect.Section 3(d) is constitutional and valid.
Novartis also argued that Section 3(d) was vague and violated India’s TRIPS obligations. The Court rejected this, affirming that the clause serves India’s constitutional goal of balancing patent protection with public health.
In simple terms: Novartis lost. The Court refused the patent for Glivec’s beta-crystalline form because the company didn’t prove enhanced therapeutic efficacy over known imatinib.
Why This Case Matters
The Novartis ruling didn’t just affect one company - it redefined India’s approach to pharmaceutical patents.
1. It drew a hard line against evergreening.
Patent applicants can’t repackage old drugs with marginal improvements and expect extended monopolies.2. It clarified the meaning of efficacy.
Only therapeutic improvement counts - not manufacturing convenience or better shelf-life, unless it translates into a measurable therapeutic benefit.3. It changed patent-filing behavior.
Innovators now file with more detailed experimental data and often combine patent and trade-secret strategies to protect incremental advances.4. It influenced global perception.
The judgment showcased India’s independent stance on intellectual-property policy - pro-innovation, yet pro-access. The case is now cited in WTO and UN policy discussions on balancing patents and public health.What Section 3(d) Means for You
If you’re a pharma startup, R&D lab, or SME working on formulations, salts, or combinations, this judgment directly affects how your applications are examined in India.
For innovators
You need comparative data showing that your new form, salt, or isomer improves therapeutic performance in patients or models.
Merely improving bioavailability, flow, or stability won’t suffice unless you show how these improvements enhance clinical outcomes.
Include this data in your specification or post-filing submissions. The patent office can’t infer efficacy—it must see evidence.
For generics and competitors
Section 3(d) gives a strong ground for pre-grant or post-grant oppositions.
Opponents can argue lack of enhanced efficacy and provide scientific literature to show the claimed compound is a “new form” of an old one.
The burden then shifts to the applicant to rebut with solid data.
The Evidence Matrix: Proving ‘Enhanced Efficacy’
After Novartis, examiners and courts look carefully at the type of evidence applicants produce. Here’s what usually helps or hurts your case:
Type of Data | Helps (if linked to therapeutic effect) | Notes |
Clinical or in-vivo studies | ✅ Strongest evidence | Directly shows improved treatment outcomes |
Pharmacodynamic (PD) data | ✅ Useful | Must correlate to therapeutic improvement |
Pharmacokinetic (PK) / bioavailability data | ⚠️ Partial | Insufficient unless tied to clinical efficacy |
Stability or shelf-life data | ⚠️ Weak alone | May support formulation claims but not therapeutic efficacy |
Solubility / flowability data | ❌ Not enough | Considered physicochemical, not therapeutic |
For example, if your polymorph dissolves better in water but delivers the same patient outcome, it will fail Section 3(d). If it dissolves better and provides faster onset or improved safety in trials, you have a case.
Drafting & Prosecution Strategies to Survive 3(d)
1. Frame the invention clearly.
If it’s a new chemical entity (NCE), state it boldly and differentiate it from prior art in the background section. For new forms, identify the known substance and explain precisely how the new form improves therapeutic outcomes.
2. Disclose comparative data early.
Include experimental results comparing the new form with the known substance. Label graphs, tables, or clinical summaries clearly.
3. Draft multiple claim sets.
Keep primary claims for the molecule and fallback claims for formulations, processes, or combinations. If 3(d) knocks out your main claim, you might still protect a process or composition.
4. Use precise scientific language.
Avoid vague terms like “improved properties” or “better results.” Replace them with measurable parameters (e.g., “increased AUC leading to 30 % higher remission rate”).
5. Respond to examination intelligently.
If you receive a Section 3(d) objection, first ensure the examiner has identified the known substance. A 2022 Delhi High Court decision in DS Biopharma v. Controller of Patents held that examiners must state this clearly; otherwise, the objection is incomplete. Use that precedent to your advantage.
Opposition and Litigation Playbook
Under the Patents Act, any person can file:
a Pre-grant opposition under Section 25(1) (before the patent is granted), or
a Post-grant opposition under Section 25(2) (within one year after grant).
One common ground for both is “the invention is not patentable under this Act”, which includes Section 3(d).
Practical tip for applicants:
File robust data upfront - once opposition starts, you can’t easily introduce new experiments.
Practical tip for opponents:
When preparing an opposition, cite scientific literature showing that the claimed substance is structurally similar to an earlier known compound and lacks evidence of enhanced efficacy.
In some cases, litigation continues through revocation proceedings under Section 64, or appeals to the High Courts.
Other Key Cases After Novartis
The Novartis decision set the benchmark, but later cases refined its application.
F. Hoffmann-La Roche Ltd. v. Cipla Ltd. (Delhi High Court, 2008 and 2015)
Clarified that comparative data must be meaningful. Roche’s argument on polymorph advantages failed because improvements in stability didn’t equate to therapeutic benefit.Ajanta Pharma Ltd. v. Allergan Inc. (IPAB, 2013)
Distinguished between new forms and combinations. If a combination shows synergistic efficacy, it can be patentable. This case helps formulators building combo drugs.DS Biopharma v. Controller of Patents (Delhi High Court, 2022)
Held that when invoking Section 3(d), the examiner must identify the known substance first. Applicants can rely on this to demand precision in examination.Novozymes v. Controller (Madras High Court, 2023)
Expanded Section 3(d)’s application beyond small molecules to biochemical inventions like enzymes—confirming that the test for “enhanced efficacy” applies across life-science sectors.
Each of these rulings reinforces that Indian patent offices expect real, demonstrable therapeutic advantage for any claim that touches Section 3(d).
Common Questions Answered
Q1. What exactly counts as “enhanced efficacy”?
A measurable therapeutic improvement in the patient or biological system—better cure rate, fewer side effects, improved bio-response, etc.
Q2. Is higher bioavailability enough?
Not by itself. The Supreme Court said increased absorption doesn’t automatically improve therapeutic effect unless supported by data linking the two.
Q3. Can combinations of drugs be patented?
Yes, but you must show synergistic efficacy (that the combo works better than the sum of its parts). Section 3(e) applies here as well.
Q4. What if my drug form has better stability or shelf-life?
Those can support formulation or process patents, but not product patents under 3(d) unless they affect therapy outcomes.
Q5. How can IP services help?
A qualified patent agent or attorney can help craft specifications that pre-empt 3(d) objections, design comparative studies, and handle oppositions strategically.
The Business Impact
The Novartis decision had commercial ripple effects. Generic manufacturers could market imatinib in India at a fraction of the price, expanding patient access. For innovators, it underscored the need to design stronger patent portfolios—covering not just molecules but formulations, processes, delivery systems, and brand protection through trademarks.
For Indian R&D-based firms, the case signaled opportunity. If they can show genuine therapeutic improvements, Section 3(d) won’t block them—it only filters superficial claims.
How IP Consultants Help You Navigate Section 3(d)
For most inventors and SMEs, the challenge isn’t understanding the law- it’s applying it. Here’s where professional IP support matters:
Patentability Opinion: An early-stage evaluation to check if your new form passes the 3(d) test.
Specification Drafting: Writing with technical depth and legal precision to demonstrate efficacy improvements.
Evidence Planning: Advising on what clinical, pharmacological, or biochemical data to generate before filing.
Opposition Defence: Preparing scientific rebuttals when competitors challenge your patent.
Portfolio Strategy: Combining patents, trade secrets, and trademarks to protect incremental innovation.
Practical Checklist Before Filing in India
Identify the closest known compound and prepare comparative data.
Document all experimental protocols (animal, in-vitro, or clinical).
Quantify therapeutic improvement in measurable parameters.
Include data tables or graphs in your specification.
Prepare a fallback claim set (formulation/process/use).
Verify that your patent draft explains why the improvement occurs.
File before public disclosure or clinical trials.
Budget for pre-grant opposition - expect scrutiny.
Consult an IP professional early.
Keep evidence ready even post-grant for potential litigation.
Conclusion
Novartis AG v. Union of India wasn’t just a legal setback for one company - it was a defining moment in how India views pharmaceutical innovation. Section 3(d) doesn’t punish innovation; it demands proof. It tells inventors: show us that your discovery truly helps patients more than what already exists.
For Indian innovators, that’s both a challenge and a chance - to build stronger, evidence-driven patents that stand up in court and in the market.
If you’re developing a new formulation, compound, or process, start early with a solid IP strategy. Generate your evidence, draft smartly, and consult professionals who understand both science and law.
After all, the difference between a rejected patent and a market-shaping innovation often lies not in the molecule, but in the story your patent tells.
